ArticleBritish journal of clinical pharmacology2026
Tacrolimus exposure during pregnancy in kidney and liver transplantation recipients: A comparison between whole blood and plasma concentration-to-dose ratios.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tacrolimus exposure during pregnancy in kidney and liver transplantation recipients: A comparison between whole blood and plasma concentration-to-dose ratios.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTacrolimus monitoring is generally performed in whole blood (WB). Most (>85%) of circulating tacrolimus is bound to red blood cells. During pregnancy, WB monitoring might be suboptimal because of physiological changes including increased plasma volume and decreased haematocrit. Therefore, plasma tacrolimus monitoring might better indicate potential dosage needs in pregnant women.
methodsThis prospective single-centre cohort study aimed to assess and compare tacrolimus WB and plasma concentration-to-dose (C/D) ratios before, during, and after pregnancy in kidney or liver transplant recipients. Linear mixed model analysis was used.
resultsNine women with 10 pregnancies were included. Based on WB tacrolimus concentrations, the median prescribed dosage significantly increased from 3 pre-pregnancy to 7.5 mg/day (+150%) in the third trimester (p < .001). The correlation between plasma and WB tacrolimus concentrations decreased throughout pregnancy with a correlation coefficient of 0.70 in the first trimester, 0.41 in the second and 0.30 in the third trimester of pregnancy. Median WB tacrolimus C/D ratios significantly decreased from 1.48 pre-pregnancy to 0.58 in the second and third trimester (-61%) (overall time effect p < .001). The effect of time became non-significant after adjusting for haematocrit (p = .40). Median plasma tacrolimus C/D ratios decreased from 0.03 pre-pregnancy to 0.02 in the first trimester (-33%) and remained stable afterward (overall time effect p = 0.33) and was not affected by haematocrit.
conclusionOur findings suggest that increasing dosages targeting WB tacrolimus concentrations may not be necessary during pregnancy based on plasma tacrolimus concentrations. However, larger studies are needed to confirm the findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.